• Proteina announced a KRW 7.3 billion private placement of 151,886 registered convertible preferred shares on November 4, 2026.
• The issue price of KRW 48,061 per share represents a 2.23% premium to the reference price.
• Proceeds will allocate KRW 5.2 billion to AI Biofoundry facilities, with KRW 2.1 billion funding platform research and drug-candidate development.
• Payment is due November 12, 2026; all shares carry a one-year lockup.
• The preferred shares initially convert one-for-one into common shares, with conversion requests permitted from November 13, 2027, through October 13, 2031.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Proteina Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261104000319), on November 04, 2026, and is solely responsible for the information contained therein.